Last reviewed 2026-04-23 · How we verify

Quinvaxem in single dose vials

Quinvaxem is a pentavalent conjugate vaccine that provides immunization against five bacterial pathogens by stimulating antibody and cellular immune responses.

Quinvaxem is a pentavalent conjugate vaccine that provides immunization against five bacterial pathogens by stimulating antibody and cellular immune responses. Used for Prevention of invasive disease caused by Haemophilus influenzae type b, Prevention of meningococcal disease (serogroups A and C), Prevention of pneumococcal disease.

At a glance

Mechanism of action

Quinvaxem combines conjugated polysaccharide antigens from Haemophilus influenzae type b, Neisseria meningitidis serogroups A and C, Streptococcus pneumoniae, and Vibrio cholerae to elicit protective immunity. The conjugation of polysaccharides to protein carriers enhances immunogenicity, particularly in infants and young children, by promoting T-cell dependent B-cell responses and long-lasting antibody production.

Approved indications

• Prevention of invasive disease caused by Haemophilus influenzae type b
• Prevention of meningococcal disease (serogroups A and C)
• Prevention of pneumococcal disease
• Prevention of cholera

Common side effects

• Injection site reactions (pain, redness, swelling)
• Fever
• Irritability
• Drowsiness

Key clinical trials

• A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Quinvaxem in single dose vials CI brief — competitive landscape report
• Quinvaxem in single dose vials updates RSS · CI watch RSS
• Crucell Holland BV portfolio CI